<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02439307</url>
  </required_header>
  <id_info>
    <org_study_id>F-CNIC-2013-55</org_study_id>
    <nct_id>NCT02439307</nct_id>
  </id_info>
  <brief_title>Effect of Rifaximin on Minimal Hepatic Encephalopathy and Small Intestinal Bacterial Overgrowth</brief_title>
  <official_title>Effect of Rifaximin on Minimal Hepatic Encephalopathy and Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 46 patients diagnosed with liver cirrhosis will be recruited. All patients will be
      evaluated with five psychometric tests and critical flicker frequency to diagnosis minimal
      hepatic encephalopathy (MHE). A breath test sample will be performed in all patients with MHE
      with 10 g of lactulose to establish the diagnosis of small intestinal bacterial overgrowth
      (SIBO). Patients diagnosed with EHM and SIBO will be randomized to receive per day 1200 mg of
      rifaximin (group A) or placebo (group B) for 2 weeks. A complete medical history, nutritional
      assessment, biochemical studies, and evaluation of quality of life will be performed in all
      patients included in the study. Besides the initial visit, patients will receive subsequent
      care 2, 4, 8, 12, and 24 weeks after the beginning of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MHE impairs the quality of life, increases the risk of motor vehicle accidents, and
      mortality. Currently, there is no consensus on treatment and yet there are few proven
      treatment options. Among the factors associated with MHE, is the small intestinal bacterial
      overgrowth (SIBO) present in 38.6% of patients with MHE. Rifaximin is a broad spectrum
      antimicrobial administered orally, with low risk of inducing bacterial resistance, and has
      been used in the treatment of MHE. It is unknown if the beneficial effect on MHE is
      associated with the elimination of SIBO and its efficacy when administered in patients with
      simultaneous diagnosis of MHE and SIBO was never been evaluated. The aim of our study is to
      evaluate the effect of rifaximin on MHE and SIBO in patients with cirrhosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reversal of small intestinal bacterial overgrowth</measure>
    <time_frame>2 weeks</time_frame>
    <description>Analyze the number of patients who reverts the small intestinal bacterial overgrowth after the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 weeks</time_frame>
    <description>Quality of life will be evaluated with the Chronic Liver Disease Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reversal of minimal hepatic encephalopathy</measure>
    <time_frame>2 weeks</time_frame>
    <description>Analyze the number of patients who reverts the minimal hepatic encephalopathy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Small Intestinal Bacterial Overgrowth</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Rifaximin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive per day 1200 mg of rifaximin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive a placebo of rifaximin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>1200 mg of rifaximin for 2 weeks.</description>
    <arm_group_label>Rifaximin</arm_group_label>
    <other_name>Antibiotic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 2 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Action lacks substance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of cirrhosis of any etiology

          -  Men and women between 18 and 70 years.

          -  Patients diagnosed with minimal hepatic encephalopathy and small intestinal bacterial
             overgrowth

          -  Right-holders of the Mexican Social Security Institute

          -  Patients who agree to participate in the study and signed the informed consent

        Exclusion Criteria:

          -  Recent history of alcohol abuse and/or drugs (less than 6 weeks).

          -  Illiterate

          -  Alcoholic cirrhosis

          -  History and/or diagnosis of overt hepatic encephalopathy

          -  Consumption of psychotropic medications (benzodiazepines, antiepileptics)

          -  Patients under treatment with lactulose, lacitol, rifaximin, neomycin, metronidazole
             and/or fiber supplements.

          -  History of chronic renal disease or heart failure

          -  Patients with gastrointestinal bleeding

          -  History of neurological or psychiatric disorders that affect the ability to develop
             neuropsychological tests

          -  Patients with diarrhea

          -  Diagnosis of liver cancer

          -  Patients with ophthalmologic disorders

          -  Patients taking antibiotics 30 days before the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Segundo Moran</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Segundo Moran, MD</last_name>
    <phone>525556276900</phone>
    <phone_ext>22363</phone_ext>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aline Mina, Nutr</last_name>
    <phone>525556276900</phone>
    <phone_ext>22363</phone_ext>
    <email>aline_mina@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro Medico Nacional Siglo XXI</name>
      <address>
        <city>Mexico</city>
        <state>Ciudad de Mexico</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Segundo Moran, MD</last_name>
      <phone>525556276900</phone>
      <phone_ext>22363</phone_ext>
      <email>segundomoran@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Aline Mina, Nutr</last_name>
      <phone>5626900</phone>
      <phone_ext>22363</phone_ext>
      <email>aline_mina@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Coordinación de Investigación en Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Segundo Moran Villota</investigator_full_name>
    <investigator_title>Titular B</investigator_title>
  </responsible_party>
  <keyword>Rifaximin</keyword>
  <keyword>Minimal hepatic encephalopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

